Kandu, Inc. reported results from a post-market randomized controlled trial showing that its FDA-cleared IpsiHand brain-computer interface system delivered clinically meaningful improvements in upper extremity motor function among chronic stroke survivors, outperforming standard at-home exercise therapy in a population years removed from their initial stroke.

The data, presented at the International Stroke Conference 2026, represent the first randomized controlled trial evaluating a non-invasive, FDA-cleared brain-computer interface therapy in chronic stroke rehabilitation, positioning the IpsiHand system as a rare example of late-stage neurorehabilitation technology backed by prospective comparative evidence.

Why a randomized post-market trial matters in a field dominated by early recovery assumptions and small studies

Stroke rehabilitation has long operated under an implicit ceiling. Clinical practice and reimbursement models have been built around the assumption that meaningful motor recovery largely plateaus within the first few months after a cerebrovascular event. While neuroplasticity is well established in theory, durable functional gains years after stroke have been difficult to demonstrate at scale, particularly in randomized trials.

Against this backdrop, a post-market randomized controlled study carries unusual weight. Many neurorehabilitation devices reach clinical use through regulatory pathways that emphasize safety and feasibility rather than comparative effectiveness. The decision by the U.S.-based medical device company to conduct a randomized trial after regulatory clearance signals confidence not only in the mechanism of action, but in the system’s ability to outperform usual care under real-world conditions.

Industry observers note that post-market trials are especially relevant in rehabilitation, where patient heterogeneity, adherence challenges, and long timelines often dilute measurable benefit. Demonstrating superiority over a home exercise program, rather than an artificial control, raises the bar for clinical relevance.

Interpreting the magnitude of benefit and why the number needed to treat stands out

The trial reported a mean improvement of 6.0 points on the Upper Extremity Fugl-Meyer scale for patients using the brain-computer interface therapy, compared with a 1.5-point improvement in the control group. This translated into a 4.5-point treatment advantage, exceeding the established minimal clinically important difference threshold.

What has drawn particular attention is the reported number needed to treat of 2.2 for one patient to achieve a clinically meaningful functional improvement. In rehabilitation research, where effect sizes are often modest and responder rates inconsistent, such a low number suggests a concentrated and reproducible benefit.

Clinicians tracking stroke outcomes are likely to scrutinize whether this effect reflects patient selection, engagement intensity, or a genuinely differentiated neurophysiological mechanism. The enrolled population had a mean time since stroke of more than five years, which reduces the likelihood that spontaneous recovery or delayed natural improvement explains the findings.

What engaging ipsilateral motor intent signals reveals about neurorehabilitation strategy

The IpsiHand system is designed around a counterintuitive principle in stroke recovery. Traditional rehabilitation strategies focus on retraining contralateral motor pathways damaged by stroke. The brain-computer interface instead detects preserved ipsilateral motor intent signals from the unaffected hemisphere and uses them to drive assisted movement of the impaired limb.

Neuroscience researchers have long debated the clinical utility of ipsilateral motor pathways. While their existence is well documented, translating them into functional recovery has remained elusive. The randomized data suggest that systematically engaging these signals through a closed-loop, intent-driven interface may unlock a previously underutilized recovery channel.

If replicated, this approach could influence how future neurorehabilitation devices are designed, shifting emphasis from damaged pathways toward compensatory neural circuits that remain accessible years after injury.

At-home deployment as a structural advantage rather than a convenience feature

Beyond the neurological mechanism, the at-home nature of the therapy represents a structural shift in how rehabilitation can be delivered. Patients in the study completed therapy five times per week over twelve weeks without relying on frequent in-clinic visits.

Health system planners increasingly recognize that access, rather than efficacy alone, limits rehabilitation outcomes. Workforce shortages, transportation barriers, and reimbursement caps often truncate therapy long before patients exhaust their recovery potential.

Regulatory watchers suggest that the system’s status as prescribed durable medical equipment, rather than an episodic therapy service, could influence payer conversations. Devices that enable ongoing, independent use may align more naturally with value-based care models than traditional session-based rehabilitation.

Regulatory implications of post-clearance evidence in a breakthrough-designated device

The IpsiHand system received U.S. Food and Drug Administration clearance in 2021 through a de novo pathway with Breakthrough Device designation. While this facilitated earlier patient access, it also meant that large-scale comparative data were not required pre-clearance.

From a regulatory perspective, the emergence of randomized evidence post-clearance strengthens the device’s position in future label discussions, reimbursement negotiations, and potential guideline inclusion. Regulators are unlikely to revisit clearance status, but payers and professional societies may increasingly look to this trial as a benchmark for evidence quality in brain-computer interface rehabilitation.

Industry observers also note that early trial termination for efficacy, while statistically justified, can complicate interpretation. Longer follow-up and replication in broader populations will be important to confirm durability and generalizability.

What this changes for chronic stroke patients and clinicians managing long-term disability

Perhaps the most consequential implication is conceptual rather than technical. Chronic stroke patients are frequently told that functional gains beyond a certain point are unlikely. This narrative shapes motivation, therapy intensity, and clinical decision-making.

Data suggesting that more than half of treated patients achieved clinically meaningful improvement years after stroke directly challenge this paradigm. Clinicians may begin to reconsider whether the absence of improvement reflects biological limits or limitations in available tools.

That said, expectations must be tempered. Not all patients responded, and the therapy targets upper extremity motor function rather than global neurological recovery. The system does not eliminate the need for conventional rehabilitation, but it may extend the window during which recovery remains possible.

Commercial and adoption considerations that remain unresolved

Despite the positive data, several questions remain open. Reimbursement pathways for brain-computer interface rehabilitation are still evolving, and payer acceptance will depend on cost-effectiveness analyses beyond clinical endpoints.

Manufacturing scalability, clinician training requirements, and patient adherence outside trial settings will also shape adoption. Real-world evidence suggesting continued improvement with longer-term use is encouraging, but prospective confirmation will be needed to persuade conservative health systems.

Competition is another factor. As interest in neurotechnology accelerates, other companies are exploring invasive and non-invasive brain-computer interfaces for rehabilitation. The extent to which randomized evidence becomes an industry expectation could reshape competitive dynamics.

What clinicians, regulators, and industry observers are likely to watch next

The next inflection point will be replication. Additional randomized studies, potentially in broader stroke populations or different impairment profiles, will test whether the observed effect is consistent.

Longer-term outcome data will be critical to determine whether gains plateau or continue with sustained use. Payers will also look for evidence that functional improvements translate into reduced caregiver burden or downstream healthcare utilization.

For regulators and policymakers, the trial raises a broader question. If chronic neurological recovery is more modifiable than previously assumed, rehabilitation policy may need to evolve alongside technology.

Taken together, the findings suggest that brain-computer interfaces may be moving from experimental promise toward practical relevance in chronic stroke care, not by replacing rehabilitation, but by extending its reach beyond traditional limits.

  brain-computer interface, chronic stroke rehabilitation, IpsiHand System, Kandu Inc, neurorehabilitation technology, stroke recovery devices